Breast Cancer Staging (TNM/AJCC 8th)
Stages breast cancer by the AJCC 8th edition anatomic stage groups (TNM). Guides adjuvant therapy, sentinel node biopsy, and radiotherapy decisions.
Score interpretation
Tis N0 M0.
→ Surgery (breast-conserving with radiotherapy, or mastectomy); MDT discussion (NICE NG101).
T1 N0 M0 — early breast cancer.
→ Breast-conserving surgery or mastectomy; SLNB; adjuvant radiotherapy post-BCS; receptor-guided systemic therapy (hormone+/-chemo); Oncotype DX if HR+/HER2- N0
T0–1 with nodal micrometastases only — early breast cancer.
→ Breast-conserving surgery or mastectomy; SLNB; adjuvant radiotherapy post-BCS; receptor-guided systemic therapy (hormone+/-chemo); Oncotype DX if HR+/HER2- N0
T0–1 N1 or T2 N0 — early breast cancer.
→ Breast-conserving surgery or mastectomy; SLNB; adjuvant radiotherapy post-BCS; receptor-guided systemic therapy (hormone+/-chemo); Oncotype DX if HR+/HER2- N0
T2 N1 or T3 N0 — early breast cancer.
→ Breast-conserving surgery or mastectomy; SLNB; adjuvant radiotherapy post-BCS; receptor-guided systemic therapy (hormone+/-chemo); Oncotype DX if HR+/HER2- N0
T0–2 N2 or T3 N1–2 — locally advanced.
→ Neoadjuvant chemotherapy to downstage; MDT planning; HER2+ add trastuzumab; axillary clearance for N+ disease; post-mastectomy radiotherapy; extended endocrine therapy (10 years) for HR+
T4 N0–2 — locally advanced.
→ Neoadjuvant chemotherapy to downstage; MDT planning; HER2+ add trastuzumab; axillary clearance for N+ disease; post-mastectomy radiotherapy; extended endocrine therapy (10 years) for HR+
Any T N3 — locally advanced.
→ Neoadjuvant chemotherapy to downstage; MDT planning; HER2+ add trastuzumab; axillary clearance for N+ disease; post-mastectomy radiotherapy; extended endocrine therapy (10 years) for HR+
Any T, any N, M1.
→ Palliative systemic therapy; HR+ first-line: CDK4/6 inhibitor + aromatase inhibitor; HER2+: trastuzumab + pertuzumab; BRCA1/2: PARP inhibitor; bone mets: zoledronate; clinical trial
Interpretation bands for the Breast Cancer Staging. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Indocyanine Green (Intravitreal Chromovitrectomy) · Diagnostic Dye — Vitreoretinal Surgery / ICG Angiography
- Trypan Blue 0.06% (Ophthalmic) · Ophthalmic Dye — Capsule Staining (Cataract Surgery)
- Acetylcholine 1% Intraocular Solution · Cholinergic — Intraocular Miotic (Cataract Surgery)
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.